Doctors in New Zealand—the only non-U.S. country that allows DTC advertising—call for bans

New Zealand physician groups in favor of banning DTC ads hope new healthcare regulations may present an opportunity to do that.

Just like the United States does, New Zealand allows DTC pharma advertising. And just like in the U.S., many doctors there would like to ban the ads.

Both the Royal New Zealand College of General Practitioners and the New Zealand Medical Association have come out recently with statements against DTC ads, as reported in New Zealand Doctor magazine. Both groups have called for a total ban on DTC ads, much the way the American Medical Association and American Society of Health-System Pharmacists did in the U.S.

The NZMA, in fact, has been advocating for a ban since 2006. But some anti-DTC advocates in New Zealand think they might have a new opportunity in 2017. DTC pharma ads are allowed in New Zealand under the Medicines Act of 1981, but that law is facing replacement legislation under an in-the-works Therapeutic Products Bill. The bill is comprehensive regulatory legislation that will regulate therapeutic products in New Zealand going forward, and the New Zealand government is currently working on it. A draft is expected this year.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

The way some people see it, the opportunity for a DTC ban is in that new legislation. The previous  unsuccessful Therapeutics Product Bill, introduced more than 10 years ago, included the ban of direct-to-consumer advertising—although marketing to physicians would have still been allowed. However, that original bill never made it to a legislative vote. And so far, no one is confident the current bill in progress has any similar provisions.

The Ministry of Health, which is favor of keeping DTC advertising according to New Zealand Doctor, told the publication last month that regulation is preferable to a ban on drug ads, and added that the new Therapeutics bill instead “should strengthen existing regulation.”

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.